medigraphic.com

2005, Number 2

<< Back Next >>

Rev Hosp Jua Mex 2005; 72 (2)

Bleed decrease in anatrofic litotomy in patients treated with aprotinin at the Hospital Juarez de Mexico

Viveros CC, Tejeda PS, Lugo GJA

Language: Spanish
References: 30
Page: 48-54
PDF size: 72.71 Kb.


ABSTRACT

It was made an experimental, longitudinal, prospective, observational and descriptive studio. The total sample was constituted by 25 patients, who were selected from the external consultation of urology department at the Juárez Hospital of México, they were diagnosed coraliform renal litiasis, that must be treated by an anatrofic litotomy. It was made a selection in aleatory way for 2 groups of 14 and 11 patients. In The group “A” was made an anatrofic litotmy with transoperatory application of aprotinin, the dosis was 50 mililiters thirty minutes before the surgery, and 50 mililiters after the surgery. In the group “B”, constituted by 11 patients, was made the anatrofic litotomy on the conventional way, without aprotinin. In both groups was quantified the bleeding during the surgery in the conventional way; it was made an evaluation of presence or absence of macroscopic hematuria in the 24 hours after the surgery; also was evaluated time of ischemia during the surgery, haemoglobin´s drecrease in the 48 hours after the surgery and quantification of drainage of surgical place. The average of lost bleed of the 14 patients who received aprotinin was 290.7 mililiters during the surgery, and 24 hours after the surgery 3 patients (21.4%) presented bleeding, the others 11 patients (78.6%) did not presented bleeding. The average quantify of the drainage 24 hours after the surgery was 67.5 mililiters, with variation of 20 to 250 mL. The average of surgical time of the group “A” (with application of aprotinin) was 143.5 minutes con variation of 120 to 180 minutes. The average of ischemia time was 17.5 minutes with variation of 10 to 25 minutes. The average in decrease of haemoglobin 48 hours after the surgery was 1.2 g. Just 1 patient (7.14%) presented bleeding 15 days after the surgery, and was treated with nefrectomy because of the persistent bleeding. The average of lost bleed in the group “B”, constituted by 11 patients, was 799.0 mililiters during the surgery, and 24 hours after the surgery 9 patients (81.1%) presented bleeding, the other 2 patients (18.2%) did not presented bleeding 24 hours after the surgery. The average of quantify drainage at 24 hours after the surgery was 179 mililiters. The average of surgical time was 157.7 minutes with variation of 130 to 180 minutes. The average of ischemia time was 16.7 minutes with variation of 10 to 25 minutes. The average in decrease of haemoglobin 48 hours after the surgery was 2.62 gr. Because of the value of χ2 obtained on this studio (27.51) was larger than the theoric χ2 (3.84) the investigation hypothesis has been considered significant. And with this results has been probed the effectiveness of the Aprotinin.


REFERENCES

  1. Walsh PC, Campbell MD. Urología. 7a. Ed. Tomo1. Cap. 8. Lowe FC, Brendler CB (eds.). Editorial Panamericana; 1994.

  2. Tanago EA, McAninch JW. Urología General de Smith. Cap. 42. McAninch JW (ed.). Editorial Manual Moderno; 2001, p. 691-2.

  3. Adelman B, Michelson AD, Loscalzo J, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65: 32-40.

  4. Alajmo F, Calamai G, Perna AM, et al. Highdose aprotinin: hemostatic effects in open heart operations. Ann Thoroc Surg 1989; 48: 536-9.

  5. Amris CJ. Inhibitions of fibrinolytic and thromboplastic activity by Trasylol®. Scand J Hoemat 1966; 3: 19-32.

  6. Angelini GD, Cooper GJ, Lamarra M, Bryan AJ. Unorthodox use of aprotinin to control life threatening bleeding after cardiopulmonary bypass. Lancet 1990; 1: 799-800.

  7. Bidstrup BP, Royston D, Taylor KM, Sapsford RN. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol®). J Thorac Cardiovasc Surg 1989; 97: 364-72.

  8. Bidstrup BP, Royston D, McGuiness C, et al. Aprotinin in aspirin treated patients. Perfusion 1990; 5: 77-81.

  9. Abrams CS, Ellison N, Budzynski A, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1987; 75: 128-38.

  10. Aoki N, Yoshida N. Inhibitions of platelet aggregation by proteases inhibitiors. Possible involvement of proteases in platelet aggregation.

  11. Abrams CS, Ellison N, Budzynski A, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1987; 75: 128-38.

  12. Adelman B, Michelson AD, Loscalzo J, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65: 32-40.

  13. Alajmo F, Calamai G, Perna AM, et al. Highdose aprotinin: Hemostatic effects in open heart operations. Ann Thoroc Surg 1989; 48: 536-9.

  14. Anonymous. Can drugs reduce surgical blood loss? Lancet 1988; 1: 155-6.

  15. Blood 1978; 52: 1-12.

  16. Bashein G, Nessly ML, Rice AL, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Int Med 1991; 151: 89-93.

  17. Bick R. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semen Thromb Hemost I. 1985; 249-80.

  18. Bidstrup BP, Royston Sapsford RN, Taylor KM. Effect of aprotinin on need for blood transfusions in patients with endocarditis having open heart surgery. Lancet 1988; 1: 366-7.

  19. Bisdrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55(4): 971-6.

  20. Bisdrup BP, Underwood SR, Sapsford RN. Effect of aprotinin (Trasylol®) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105(I): 147-53.

  21. Blauhut B, Gross C, Necek S, et al. Effects of high-dose aprotinin on blood loss, platelet function, ffbrinolytis, complement, and renal function after cardiopulmonary bypass.] Thorac Cardiovas Surg 1991; 101: 958-67.

  22. Blombäck B, Blombäck M, Olsson P. Action of a proteolytic enzyme inhibitor on blood coagulation in vitro. Thrombosis et diathesis haemorrhogica 1967; 18: 190-7.

  23. Blümel G, Huth K, Lasch HG. The influence of Trasylol® on experimental fat embolism. New aspects of Trasylol® therapy 4: 129-35. Schattauer, Stuttgart-New York 1970.

  24. Bode AP, Miller DT. The use of thrombin inhibitors and aprotinin in the preservation of platelets stored for transfusion. J Lab Clin Med 1989; 113: 753-8.

  25. Bode AP, Krupp CL, Miller DT. Effect of platelet activation inhibitors on the loss of gly-coprotein Ib during storage of platelet concentrates. Lab Clin Med 1990; 115: 669-79.

  26. Boldt J, Knothe C, et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993; 105(4): 705-1 I.

  27. Amris CJ. Inhibitions of fibrinolytic and thromboplastic activity by Trasylol®. Scand j Hoemat 1966; 3: 19-32.

  28. Angelini GD, Cooper Gj, Lamarra M, Bryan AJ. Unorthodox use of aprotinin to control life threatening bleeding after cardiopulmonary bypass. Lancet 1990; 1: 799-800.

  29. Aoki N, Yoshida N. Inhibitions of platelet aggregation by proteases inhibitiors. Possible involvement of proteases in platelet aggregation. Blood 1978; 52: 1-12.

  30. Bashein G, Nessly ML, Rice AL, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Int Med 1991; 151: 89-93.




2020     |     www.medigraphic.com